Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

MiMedx Group Sees FY25 Net Sales Growth In High Single-Digits As Percentage; Expects Adj. EBITDA Margin Above 20% On Full Year Basis; Expects Annual Net Sales Growth In Low double-Digits As Percentage With Adj. EBITDA Margin Above 20%

Author: Benzinga Newsdesk | April 30, 2025 04:13pm

Posted In: MDXG